Ophthalmic Education:

Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist: Appendix 1: Diabetes Control and Complications Trial (DCCT)

On this page:

• Recommended Reading
  
  
• Additional Background Reading

Recommended Reading

(No authors listed). Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 1996; 276: 1409-1415

(No authors listed). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986

(No authors listed). Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102: 647-661

(No authors listed). Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874-886 [Erratum appears in Arch Ophthalmol 1998; 116: 1469]

(No authors listed). The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995; 113: 36-51

Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389

Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-744

Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes.Diabetes Care 1998; 21, Suppl 3: C39-43

Additional Background Reading

Peterson KA. Smith CK. The DCCT findings and standards of care for diabetes. Am Fam Physician 1995; 52: 1092-1098

Leiter LA. Use of bioelectrical impedance analysis measurements in patients with diabetes. The Diabetes Control and Complications Trial Research Group. Am J Clin Nutr 1996; 64: 515S-518S

(No authors listed). Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991; 90: 450-459

(No authors listed). Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128: 517-523

(No authors listed). The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122: 561-568

(No authors listed). Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Arch Ophthalmol 1987; 105: 1344-1351

Worrall G. Results of the DCCT trial. Implications for managing our patients with diabetes. Can Fam Physician 1994; 40: 1955-1960, 1963-1965

Hoogwerf BJ, Brouhard BH. Glycemic control and complications of diabetes mellitus: practical implications of the Diabetes Control and Complications Trial (DCCT). Cleve Clin J Med 1994; 61: 34-37; quiz 80-82

(No authors listed). Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem 1987; 33: 2267-2271

(No authors listed). Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. The DCCT Research Group. Control Clin Trials 1989; 10: 83-96

(No authors listed). Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46: 1829-1839

(No authors listed). Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988; 37: 476-481

(No authors listed). Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46: 271-286

Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-880

(No authors listed). The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986; 35: 530-545

Gautier JF, Beressi JP, Leblanc H, Vexiau P, Passa P. Are the implications of the Diabetes Control and Complications Trial (DCCT) feasible in daily clinical practice? Diabetes Metab 1996; 22: 415-419

McCulloch DK, Glasgow RE, Hampson SE, Wagner E. A systematic approach to diabetes management in the post-DCCT era. Diabetes Care 1994; 17: 765-769

Moses RG, Rodgers DV, Griffiths RD. Clinic variations hold important clues to the understanding and implementation of the DCCT results. Diabetes Care 1996; 19: 178-180

Dagogo-Jack S. DCCT results and diabetes care in developing countries. Diabetes Care 1995; 18: 416-417

(No authors listed). Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care 1987; 10: 1-19

(No authors listed). Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 1990; 13: 427-433

(No authors listed). Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23: 1084-1091

Orchard TJ. From diagnosis and classification to complications and therapy. DCCT. Part II? Diabetes Control and Complications Trial. Diabetes Care 1994; 17: 326-338

Thompson CJ, Cummings JF, Chalmers J, Gould C, Newton RW. How have patients reacted to the implications of the DCCT? Diabetes Care 1996; 19: 876-879

Rubin RR. Peyrot M. Implications of the DCCT. Looking beyond tight control. Diabetes Care 1994; 17: 235-236

(No authors listed). Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care 1992; 15: 886-894

(No authors listed). Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988;11: 725-732

Harris MI, Eastman RC, Siebert C. The DCCT and medical care for diabetes in the U.S.
Diabetes Care 1994; 17: 761-764

(No authors listed). Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11: 567-573

(No authors listed). AADE position statement: Diabetes Control and Complications Trial (DCCT). Diabetes Educ 1994; 20: 106, 108

Ahern JA, Kruger DF, Gatcomb PM, Petit WA Jr, Tamborlane WV. The diabetes control and complications trial (DCCT): the trial coordinator perspective. Report by the DCCT Research Group. Diabetes Educ 1989; 15: 236-241

Ahern J, Grove N, Strand T et al. The impact of the Trial Director in the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes Educ 1993; 19: 509-512

Ahern JA, Ramchandani N, Cooper J et al. Using a primary nurse manager to implement DCCT recommendations in a large pediatric program. Diabetes Educ 2000; 26: 990-994

Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998; 42: 77-83

(No authors listed). Implementing the lessons of DCCT. Report of a national workshop under the auspices of the British Diabetic Association. Diabet Med 1994; 11: 220-228

Gibb I, Parnham AJ, Lord C et al. Standardization of glycated haemoglobin assays throughout the Northern region of England: a pilot study. Diabet Med 1997; 14: 584-588

(No authors listed). The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423

Zinman B. Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers. Diabetologia 1997; 40 Suppl 2: S88-90

Szucs TD. Smala AM. Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]. Fortschr Med 1998; 116: 34-38. German.

Leiter LA, Lukaski HC, Kenny DJ et al. The use of bioelectrical impedance analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT). Int J Obes Relat Metab Disord 1994; 18: 829-835

Purnell JQ, Hokanson JE, Marcovina SM et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146 [Erratum appears in JAMA 1998 1994; 1280: 1484]

(No authors listed). A screening algorithm to identify clinically significant changes in neuropsychological functions in the Diabetes Control and Complications Trial. DCCT Research Group. J Clin Exp Neuropsychol 1994; 16: 303-316

(No authors listed). Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab 1987; 65: 30-36

White NH, Cleary PA, Dahms W et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-812

(No authors listed). Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125: 177-188

Moses R, Rodgers D, Griffiths R. Diabetic control and hypoglycaemia in the Illawarra area of NSW, Australia: a comparison with the DCCT. J Qual Clin Pract 1995; 15: 89-97

Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group. J Am Diet Assoc 1993; 93: 758-764, 767

Anderson EJ, Richardson M, Castle G et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993; 93: 768-772

Schmidt LE, Cox MS, Buzzard IM, Cleary PA. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1994; 94: 1392-1397

Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 1159-1171

Molitch ME, Steffes MW, Cleary PA, Nathan DM. Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [corrected]. Kidney Int 1993; 43: 668-674

(No authors listed). Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47: 1703-1720

Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int 2000; 58: 1742-1750

Chrisholm DJ. The Diabetes Control and Complications Trial (DCCT). A milestone in diabetes management. Med J Aust. 1993; 159: 721-723

Nosadini R, Abaterusso C, Dalla Vestra M et al. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus. Nephrol Dial Transplant 1998; 13 Suppl 8: 44-48

Rapaport R. Sills IN. Implications of the DCCT for children and adolescents with IDDM.
N J Med 1994; 91: 227-228

(No authors listed). Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903

Schwartz R, Teramo KA. Pregnancy outcome, Diabetes Control and Complications Trial, and intensive glycemic control. Am J Obstet Gynecol 1998; 178: 416-417

(No authors listed). Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353

(No authors listed). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569

(No authors listed). Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124: 379-388

Brink SJ. How to apply the experience from the diabetes control and complications trial to children and adolescents? Ann Med 1997; 29: 425-438

(No authors listed). Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-880

Carlisle BA. The implications of diabetes control and complications trial for the pharmacy profession. Ann Pharmacother 1996; 30: 294-295

Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995; 155: 745-754

Duron F. Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial. Biomed Pharmacother 1995; 49: 278-282

Newman RJ. A method to implement the recommendations of the diabetes control and complications trial in a busy pediatric outpatient practice. Pediatr Ann 1999; 28: 594-598

Fenton CL, Clemons PM, Francis GL. How do the results of the diabetes control and complications trial relate to the practice of pediatrics: who should have intensive management? Pediatr Ann 1999; 28: 600-604

Malone JI. Lessons for pediatricians from the diabetes control and complications trial.
Pediatr Ann 1994; 23: 295-299

Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am 1997; 44: 285-300

Vinik AI, Richardson DW. Implications of the diabetes control and complications trial for persons with non-insulin-dependent diabetes mellitus. South Med J 1997; 90: 268-282

Saudek CD. Non-ophthalmologic findings of the Diabetes Control and Complications Trial.
Surv Ophthalmol 1995; 40: 157-162

Nuttall FQ. Comparison of percent total GHb with percent HbA1c in people with and without known diabetes. Diabetes Care 1998; 21: 1475-1480

Ruggiero L, Glasgow R, Dryfoos JM et al. Diabetes self-management. Self-reported recommendations and patterns in a large population. Diabetes Care 1997; 20: 568-576

Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000; 23: 1478-1485

Rosilio M, Cotton JB, Wieliczko MC et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care 1998; 21: 1146-1153

(No authors listed). Factors influencing glycemic control in young people with type 1 diabetes in Scotland: a population-based study (DIABAUD2). Diabetes Care 2001; 24: 239-244

Yokoyama H, Okudaira M, Otani T et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care 1998; 21: 1080-1085

Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG. Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care 1997; 20: 59-63

Miller CD. Phillips LS. Tate MK et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000; 23: 444-448

Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20: 725-734

Keen H. The Diabetes Control and Complications Trial (DCCT). Health Trends 1994; 26: 41-43

Tercyak KP Jr, Johnson SB, Kirkpatrick KA, Silverstein JH. Offering a randomized trial of intensive therapy for IDDM to adolescents. Reasons for refusal, patient characteristics, and recruiter effects. Diabetes Care 1998; 21: 213-215

Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20: 562-567

Next: Appendix 1: Diabetic Retinopathy Study (DRS)

Also see: Table of Contents of the Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist